Jade Biosciences (JBIO) Total Liabilities (2020 - 2026)

Jade Biosciences (JBIO) has 7 years of Total Liabilities data on file, last reported at $23.0 million in Q1 2026.

• Quarterly Total Liabilities rose 823.64% year-over-year to $23.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.0 million (up 823.64% YoY) and the FY2025 annual result came in at $17.3 million, down 85.57% from the prior year.
• Total Liabilities rose to $23.0 million in Q1 2026, from $17.3 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $119.6 million in Q4 2024 to a low of $2.5 million in Q1 2025.
• A 5-year average of $19.8 million and a median of $15.2 million in 2023 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities slumped 92.58% — and 2026, when it jumped 823.64%.
• Tracing JBIO's Total Liabilities over 5 years: stood at $8.6 million in 2022, then soared by 109.89% to $18.0 million in 2023, then soared by 565.83% to $119.6 million in 2024, then plunged by 85.57% to $17.3 million in 2025, then surged by 33.06% to $23.0 million in 2026.
• The last three Total Liabilities figures came in at $23.0 million (Q1 2026), $17.3 million (Q4 2025), and $23.1 million (Q3 2025), per Business Quant data.